Medigus Ltd. (NASDAQ: MDGS) is 20.42% higher on its value in year-to-date trading and has touched a low of $0.83 and a high of $5.15 in the current 52-week trading range. The MDGS stock was last observed hovering at around $2.30 in the last trading session, with the day’s gains setting it 0.48% off its average median price target of $158.61 for the next 12 months. It is also 98.25% off the consensus price target high of $158.61 offered by 1 analysts, but current levels are 98.25% higher than the price target low of $158.61 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $2.78, the stock is 41.54% and 27.48% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 17.42 million and changing 20.85% at the moment leaves the stock 45.87% off its SMA200. MDGS registered 30.68% gain for a year compared to 6-month gain of 41.10%. The firm has a 50-day simple moving average (SMA 50) of $2.2029 and a 200-day simple moving average (SMA200) of $1.8233.
The stock witnessed a 15.58% loss in the last 1 month and extending the period to 3 months gives it a 54.36%, and is 16.75% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.43% over the week and 9.33% over the month.
Medigus Ltd. (MDGS) has around 20 employees, a market worth around $33.94M and $0.27M in sales. Distance from 52-week low is 234.88% and -46.03% from its 52-week high.
Medigus Ltd. (MDGS) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Medigus Ltd. (MDGS) is a “Buy”. 1 analysts offering their recommendations for the stock, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Medigus Ltd. is expected to release its quarterly report on 06/02/2021..
Medigus Ltd. (MDGS) Top Institutional Holders
7 institutions hold shares in Medigus Ltd. (MDGS), with 116.63k shares held by insiders accounting for 2.82% while institutional investors hold 11.26% of the company’s shares. The shares outstanding are 14.76M, and float is at 3.78M with Short Float at 6.09%. Institutions hold 10.94% of the Float.
The top institutional shareholder in the company is Renaissance Technologies, LLC with over 0.19 million shares valued at $0.26 million. The investor’s holdings represent 1.19% of the MDGS Shares outstanding. As of Sep 29, 2020, the second largest holder is Citadel Advisors LLC with 50611.0 shares valued at $69843.0 to account for 0.32% of the shares outstanding. The other top investors are Wedbush Securities Inc which holds 14200.0 shares representing 0.09% and valued at over $19596.0, while UBS Group AG holds 0.02% of the shares totaling 2673.0 with a market value of $3688.0.